Severity
Low
FDA Drug recall · Reported July 11, 2012
Subpotent (Single Ingredient Drug): out-of-specification result for coal tar content assay.
Ranbaxy Inc. recalled Balnetar Therapeutic Tar Bath, Coal Tar USP 2.5% (from Coal Tar USP Solution, 7%), 7.5 oz… - a low-severity action.
Balnetar Therapeutic Tar Bath, Coal Tar USP 2.5% (from Coal Tar USP Solution, 7%), 7.5 oz… was recalled by Ranbaxy Inc. in July 11, 2012. Reason: Subpotent (Single Ingredient Drug): out-of-specification result for coal tar content assay.. Check the official notice for the remedy. Verify recall #D-1405-2012 with the FDA Drug before acting.
The recall
Ranbaxy Inc. issued this low-severity FDA Drug recall-Subpotent (Single Ingredient Drug): out-of-specification result for coal tar content assay..
Sourced from official FDA Drug enforcement records. Verify recall #D-1405-2012 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-1405-2012) was formally reported on July 11, 2012, with the manufacturer initiating the action on March 16, 2012. It is classified under Low severity (Class III), with a current status of Terminated. Ranbaxy Inc. is listed as the recalling firm, operating out of Princeton, NJ. Federal records list the affected scope as 2544 bottles.
The documented reason for this recall is: Subpotent (Single Ingredient Drug): out-of-specification result for coal tar content assay. Distribution data in the federal record shows the product reached: Nationwide. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls, 5 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 14,287 drugs & medications recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified low severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Low
Affected scope
2544 bottles
Related Recalls
6
5 from same agency
Balnetar Therapeutic Tar Bath, Coal Tar USP 2.5% (from Coal Tar USP Solution, 7%), 7.5 oz bottle, Distributed by Ranbaxy, Jacksonville, FL 32257, NDC 10631-106-08
Subpotent (Single Ingredient Drug): out-of-specification result for coal tar content assay.
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Low (Class III) |
| Status | Terminated |
| Recall number | D-1405-2012 |
| Date reported | July 11, 2012 |
| Date initiated | March 16, 2012 |
| Recalling firm | Ranbaxy Inc. |
| Firm location | Princeton, NJ |
| Affected scope | 2544 bottles |
| Distribution | Nationwide |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
AbbVie Inc. · 2026-06-03
Llorens Pharmaceuticals International Division, Inc. · 2026-05-27
Safecor Health, LLC · 2026-05-27
IntegraDose Compounding Services LLC · 2026-05-27
Lupin Pharmaceuticals Inc. · 2026-05-27
Compare this recall with PRED MILD, prednisolone acetate ophthalmic suspension, USP,… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported July 11, 2012. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.